Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (201-210 of 323) with videos related to

Pageof 33
Sort By:
Frontiers in Oncology|February 26, 2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trialMarco Maria Germani, Guglielmo Vetere, Mirella Giordano, et al.
BMC Cancer|April 8, 2025
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trialVincenzo Nasca, Francesca Bergamo, Luisa Foltran, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2022
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancerCarlotta Antoniotti, Federica Marmorino, Alessandra Boccaccino, et al.
Clinical Colorectal Cancer|February 23, 2023
Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)Carlo Sposito, Filippo Pietrantonio, Marianna Maspero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 StudyKohei Shitara, Sun Young Rha, Lucjan Wyrwicz, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2025
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancerLorenzo Castagnoli, Alma Franceschini, Valeria Cancila, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studiesCarlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
Scientific Reports|March 1, 2019
Prognostic impact of ATM mutations in patients with metastatic colorectal cancerGiovanni Randon, Giovanni Fucà, Daniele Rossini, et al.
JAMA Network Open|April 9, 2024
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled TrialDavide Ciardiello, Erika Martinelli, Teresa Troiani, et al.
JCO Precision Oncology|April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case SeriesMargherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
Pageof 33

Showing results (201-210 of 323) with videos related to

Sort By:
Pageof 33
Frontiers in Oncology|February 26, 2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trialMarco Maria Germani, Guglielmo Vetere, Mirella Giordano, et al.
BMC Cancer|April 8, 2025
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trialVincenzo Nasca, Francesca Bergamo, Luisa Foltran, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2022
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancerCarlotta Antoniotti, Federica Marmorino, Alessandra Boccaccino, et al.
Clinical Colorectal Cancer|February 23, 2023
Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)Carlo Sposito, Filippo Pietrantonio, Marianna Maspero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 StudyKohei Shitara, Sun Young Rha, Lucjan Wyrwicz, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2025
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancerLorenzo Castagnoli, Alma Franceschini, Valeria Cancila, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studiesCarlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
Scientific Reports|March 1, 2019
Prognostic impact of ATM mutations in patients with metastatic colorectal cancerGiovanni Randon, Giovanni Fucà, Daniele Rossini, et al.
JAMA Network Open|April 9, 2024
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled TrialDavide Ciardiello, Erika Martinelli, Teresa Troiani, et al.
JCO Precision Oncology|April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case SeriesMargherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
Pageof 33